AI Terminal
Cannovum Cannabis AG
Regulatory Filings • Dec 15, 2022
7293_rns_2022-12-15_5d0d7aa8-bc71-47e1-b3a7-5cb87d8957dd.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 15 December 2022 09:00
Cannovum AG share enters Xetra trading
EQS-News: Cannovum AG / Key word(s): Miscellaneous/Research Update
Cannovum AG share enters Xetra trading
15.12.2022 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, 15.12.2022 – The share of Cannovum AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has been included in trading on the Xetra and Frankfurt Stock Exchange. This means that Cannovum AG is now represented on Germany’s largest and most important stock exchange.
“This is an important milestone on our way to becoming one of the market leaders in the upcoming legal cannabis segment,” says Pia Marten, CEO and co-founder of Cannovum AG. “By listing on the most important German trading platform, we increase Cannovum AG’s visibility in the capital markets and make it easier for investors to profit from cannabis legalization.”
Even before the listing on the Xetra market, the first analysts reported on Cannovum AG’s stock. From Sphene Capital, an independent research firm for small and mid caps, the share has received a Buy rating with a price target of 15.30 euros.
Contact:
Klaus Madzia, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, [email protected]
Cannovum AG is the first German fully licensed cannabis company listed on the stock exchange. The shares are traded on the stock exchanges in Frankfurt/Xetra, Düsseldorf, Munich, Berlin, Hamburg and gettex. Cannovum AG is ready for the legalization of cannabis and well-prepared: both for sales through pharmacies and through licensed specialty stores and online shipping.
Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer, and manufacturer of high-quality medical cannabis products based in Berlin. Already today, Cannovum AG is a market leader in the medical cannabis sector.
Currently the company works on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies.
For more information, visit https://cannovum.com/investor-relations
15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Cannovum AG |
| Rheinsberger Str. 76/77 | |
| 10115 Berlin | |
| Germany | |
| Phone: | +49 (0)30 3982 16360 |
| E-mail: | [email protected] |
| Internet: | www.cannovum.com |
| ISIN: | DE000A2LQU21 |
| WKN: | A2LQU2 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Hamburg, Munich |
| EQS News ID: | 1513363 |
| End of News | EQS News Service |